Anixa Biosciences Inc (ANIX): Total Liabilities
$2.13M
As of 2025-10-31
$1.87M
As of 2026-07-31
-1.3%
3-year compound annual growth
+12.4%
5-year compound annual growth
-6.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | $2.13M | -21.2% | 2026-01-12, Balance as of period end |
| 2024-10-31 | $2.70M | +25.7% | 2026-01-12, Balance as of period end |
| 2023-10-31 | $2.15M | -2.8% | 2025-01-10, Balance as of period end |
| 2022-10-31 | $2.21M | +48.5% | 2024-01-16, Balance as of period end |
| 2021-10-31 | $1.49M | +25.4% | 2023-01-04, Balance as of period end |
| 2020-10-31 | $1.19M | n/a | 2022-01-04, Balance as of period end |
| No annual figure between 2017-10-31 and 2020-10-31. | |||
| 2017-10-31 | $889.5K | -80.8% | 2018-01-09, Balance as of period end |
| 2016-10-31 | $4.64M | +8.4% | 2018-01-09, Balance as of period end |
| 2015-10-31 | $4.28M | -15.1% | 2016-12-08, Balance as of period end |
| 2014-10-31 | $5.05M | -42.4% | 2015-12-23, Balance as of period end |
| 2013-10-31 | $8.76M | n/a | 2015-01-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $2.13M | -21.2% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $7.28M | -50.5% |
| Aditxt, Inc. (ADTX) | 2025-12-31 | $12.56M | -47.3% |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | $10.26M | -54.1% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $2.53M | +67.1% |
| Cingulate Inc. (CING) | 2025-12-31 | $12.56M | +69.6% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $5.06M | -48.4% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $1.85M | -85.8% |
| Mustang Bio, Inc. (MBIO) | 2025-12-31 | $8.06M | -38.8% |
Compare ANIX, RVPH, ADTX, TPST side by side · Screen every company in Pharmaceutical Preparations ↗